Therapeutic targets in idiopathic pulmonary fibrosis

Respiratory Medicine

Volumn 131, Issue , 2017, Pages 49-57

  Kolb, Martin ^a   Bonella, Francesco ^b   Wollin, Lutz ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b RUHRLANDKLINIK   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Idiopathic pulmonary fibrosis

Indexed keywords

BG 00011; BMS 986020; CC 90001; GLPG 1690; KD 025; LEBRIKIZUMAB; NINTEDANIB; PAMREVLUMAB; PBI 4050; PIRFENIDONE; PRM 151; RESPIRATORY TRACT AGENT; SAR 156597; TD 139; TIPELUKAST; UNCLASSIFIED DRUG; VOXELOTOR; ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PYRIDONE DERIVATIVE; VASCULOTROPIN RECEPTOR;

COMBINATION DRUG THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FIBROSING ALVEOLITIS; HUMAN; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; DISEASE EXACERBATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MOLECULAR TARGETED THERAPY; PYRIDONES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 85029699501     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2017.07.062     Document Type: Review

References (95)

1. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Müller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schünemann, H.J., ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011), 788–824, 10.1164/rccm.2009-040GL.
2. Hutchinson, J., Fogarty, A., Hubbard, R., McKeever, T., Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J. 46:3 (2015), 795–806, 10.1183/09031936.00185114.
3. Hopkins, R.B., Burke, N., Fell, C., Dion, G., Kolb, M., Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur. Respir. J. 48:1 (2016), 187–195, 10.1183/13993003.01504-2015.
4. Yount, S.E., Beaumont, J.L., Chen, S.Y., Kaiser, K., Wortman, K., Van Brunt, D.L., Swigris, J., Cella, D., Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung 194:2 (2016), 227–234, 10.1007/s00408-016-9850-y.
5. Selman, M., King, T.E., Pardo, A., American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern Med. 134:2 (2001), 136–151, 10.7326/0003-4819-134-2-200101160-00015.
6. King, T.E. Jr., Pardo, A., Selman, M., Idiopathic pulmonary fibrosis. Lancet 378:9807 (2011), 1949–1961, 10.1016/S0140-6736(11)60052-4.
7. Bellaye, P.S., Kolb, M., Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. BMC Med., 13, 2015, 176, 10.1186/s12916-015-0412-6.
8. Noble, P.W., Barkauskas, C.E., Jiang, D., Pulmonary fibrosis: patterns and perpetrators. J. Clin. Invest. 122:8 (2012), 2756–2762, 10.1172/JCI60323.
9. Wuyts, W.A., Agostini, C., Antoniou, K.M., Bouros, D., Chambers, R.C., Cottin, V., Egan, J.J., Lambrecht, B.N., Lories, R., Parfrey, H., Prasse, A., Robalo-Cordeiro, C., Verbeken, E., Verschakelen, J.A., Wells, A.U., Verleden, G.M., The pathogenesis of pulmonary fibrosis: a moving target. Eur. Respir. J. 41:5 (2013), 1207–1218, 10.1183/09031936.00073012.
10. Froese, A.R., Shimbori, C., Bellaye, P.S., Inman, M., Obex, S., Fatima, S., Jenkins, G., Gauldie, J., Ask, K., Kolb, M., Stretch-induced activation of transforming growth factor-β1 in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 194:1 (2016), 84–96, 10.1164/rccm.201508-1638OC.
11. Farkas, L., Kolb, M., Pulmonary microcirculation in interstitial lung disease. Proc. Am. Thorac. Soc. 8:6 (2011), 516–521, 10.1513/pats.201101-007MW.
12. Hanumegowda, C., Farkas, L., Kolb, M., Angiogenesis in pulmonary fibrosis: too much or not enough?. Chest 142:1 (2012), 200–207, 10.1378/chest.11-1962.
13. Grimminger, F., Günther, A., Vancheri, C., The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur. Respir. J. 45:5 (2015), 1426–1433, 10.1183/09031936.00149614.
14. Spagnolo, P., Tzouvelekis, A., Maher, T.M., Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr. Opin. Pulm. Med. 21:5 (2015), 470–478.
15. Roche, Esbriet (pirfenidone) summary of product characteristics. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf, October 2015 Accessed 2 December 2016.
16. King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., Fagan, E.A., Glaspole, I., Glassberg, M.K., Gorina, E., Hopkins, P.M., Kardatzke, D., Lancaster, L., Lederer, D.J., Nathan, S.D., Pereira, C.A., Sahn, S.A., Sussman, R., Swigris, J.J., Noble, P.W., ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2083–2092, 10.1056/NEJMoa1402582.
17. Noble, P.W., Albera, C., Bradford, W.Z., Costabel, U., Glassberg, M.K., Kardatzke, D., King, T.E. Jr., Lancaster, L., Sahn, S.A., Szwarcberg, J., Valeyre, D., du Bois, R.M., CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:9779 (2011), 1760–1769, 10.1016/S0140-6736(11)60405-4.
18. Giri, S.N., Leonard, S., Shi, X., Margolin, S.B., Vallyathan, V., Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Pathol. Toxicol. Oncol. 18:3 (1999), 169–177.
19. Misra, H.P., Rabideau, C., Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell Biochem. 204:1–2 (2000), 119–126 doi: 0.1023/A:1007023532508.
20. Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., Vancheri, C., Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur. J. Pharm. Sci. 58 (2014), 13–19, 10.1016/j.ejps.2014.02.014.
21. Lehtonen, S.T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M.C., Kaarteenaho, R., Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir. Res., 17(1), 2016, 14, 10.1186/s12931-016-0328-5.
22. Nakayama, S., Mukae, H., Sakamoto, N., Kakugawa, T., Yoshioka, S., Soda, H., Oku, H., Urata, Y., Kondo, T., Kubota, H., Nagata, K., Kohno, S., Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 82:3–4 (2008), 210–217, 10.1016/j.lfs.2007.11.003.
23. Inomata, M., Kamio, K., Azuma, A.L., Matsuda, K., Kokuho, N., Miura, Y., Hayashi, H., Nei, T., Fujita, K., Saito, Y., Gemma, A., Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir. Res., 15, 2014, 16, 10.1186/1465-9921-15-16.
24. Kakugawa, T., Mukae, H., Hayashi, T., Ishii, H., Abe, K., Fujii, T., Oku, H., Miyazaki, M., Kadota, J., Kohno, S., Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur. Respir. J. 24:1 (2004), 57–65, 10.1183/09031936.04.00120803.
25. Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., Arimura, A., Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 590:1–3 (2008), 400–408, 10.1016/j.ejphar.2008.06.046.
26. Ingelheim, Boehringer, OFEV (nintedanib) summary of product characteristics. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003821/WC500182474.pdf, October 2016 Accessed 2 December 2016.
27. Richeldi, L., Costabel, U., Selman, M., Kim, D.S., Hansell, D.M., Nicholson, A.G., Brown, K.K., Flaherty, K.R., Noble, P.W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klueglich, M., du Bois, R.M., Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365:12 (2011), 1079–1087, 10.1056/NEJMoa1103690.
28. Richeldi, L., du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., Costabel, U., Cottin, V., Flaherty, K.R., Hansell, D.M., Inoue, Y., Kim, D.S., Kolb, M., Nicholson, A.G., Noble, P.W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., Collard, H.R., INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2071–2082, 10.1056/NEJMoa1402584.
29. Richeldi, L., Cottin, V., du Bois, R.M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., Brown, K.K., Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir. Med. 113 (2016), 74–79, 10.1016/j.rmed.2016.02.001.
30. Hilberg, F., Roth, G.J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., Heckel, A., Rettig, W.J., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68:12 (2008), 4774–4782, 10.1158/0008-5472.CAN-07-6307.
31. Hostettler, K.E., Zhong, J., Papakonstantinou, E., Karakiulakis, G., Tamm, M., Seidel, P., Sun, Q., Mandal, J., Lardinois, D., Lambers, C., Roth, M., Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir. Res., 15, 2014, 157, 10.1186/s12931-014-0157-3.
32. Sato, S., Goto, H., Abe, S., Kishi, M., Kinoshita, K., Azuma, M., Takezaki, A., Kishi, J., Aono, Y., Hanibuchi, M., Nishioka, Y., Effect of nintedanib (BIBF1120) on fibrocyte-induced fibroblast activation. Am. J. Respir. Crit. Care Med., 189, 2014 A2021.
33. Schuett, J., Ostermann, A.M., Wollin, L., The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF. Eur. Respir. J., 46(Suppl. 59), 2015 PA3846.
34. Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., Ryffel, B., Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 349:2 (2014), 209–220, 10.1124/jpet.113.208223.
35. Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K.E., Stowasser, S., Kolb, M., Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 45:5 (2015), 1434–1445, 10.1183/09031936.00174914.
36. Morizumi, S., Sato, S., Abe, S., Okazaki, H., Chen, Y., Goto, H., Aono, Y., Ogawa, H., Hanibuchi, M., Uehara, H., Nishioka, Y., Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity. Eur. Respir. J., 48(Suppl.60), 2016, PA778.
37. Wollin, L., Schuett, J., Ostermann, A.M., Herrmann, F., The effect of nintedanib on platelet derived growth factor-stimulated contraction of human primary lung fibroblasts. Am. J. Respir. Crit. Care Med., 193, 2016 A2384.
38. Ackermann, M., Kim, Y.O., Wagner, W.L., Schuppan, D., Valenzuela, C.D., Mentzer, S.J., Kreuz, S., Stiller, D., Wollin, L., Konerding, M.A., Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis, 2017 Mar 10, 10.1007/s10456-017-9543-z [Epub ahead of print].
39. Tandon, K., Herrmann, F., Ayaub, E., Parthasarathy, P., Ackermann, M., Inman, M.D., Kolb, M.R.J., Wollin, L., Ask, K., Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor. Am. J. Respir. Crit. Care Med., 195, 2017 A2397.
40. Wermuth, P.J., Jimenez, S.A., The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin. Transl. Med., 4, 2015, 2, 10.1186/s40169-015-0047-4.
41. Ford, P., Schambye, H., MacKinnon, A.C., Kemper, C., Thomas, T., Knott, O., Febbraro, S., Td139, a novel inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). Results from the first in human study in healthy volunteers. Am. J. Respir. Crit. Care Med., 191, 2015 A6441.
42. MacKinnon, A.C., Gibbons, M.A., Farnworth, S.L., Leffler, H., Nilsson, U.J., Delaine, T., Simpson, A.J., Forbes, S.J., Hirani, N., Gauldie, J., Sethi, T., Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am. J. Respir. Crit. Care Med. 185:5 (2012), 537–546, 10.1164/rccm.201106-0965OC.
43. MacKinnon, A.C., Hirani, N., Nillson, U., Leffler, H., Schambye, H., Sethi, T., An inhaled galectin-3 inhibitor, TD139, inhibits bleomycin-induced lung fibrosis and decreases galectin-3 expression in human IPF lung macrophages. September 2014, International Colloquium on Lung and Airway Fibrosis (ICLAF), Mont Tremblant, Quebec, Canada, 20–24 Available at: http://iclaf.com/conference/index.php/2014/ICLAF/paper/view/200 Accessed 2 December 2016.
44. Hirani, N., Mackinnon, A., Nicol, L., Walker, J., Ford, P., Schambye, H., Pederson, A., Nilsson, U., Leffler, H., Thomas, T., Francombe, D., Simpson, J., Gibbons, M., Maher, T.M., TD139, a novel inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). Results from the first in (IPF) patients study. Am. J. Respir. Crit. Care Med., 195, 2017 A7560.
45. Kihara, Y., Mizuno, H., Chun, J., Lysophospholipid receptors in drug discovery. Exp. Cell Res. 333:2 (2015), 171–177, 10.1016/j.yexcr.2014.11.020.
46. Stoddard, N.C., Chun, J., Promising pharmacological directions in the world of lysophosphatidic acid signaling. Biomol. Ther. Seoul. 23:1 (2015), 1–11, 10.4062/biomolther.2014.109.
47. Swaney, J.S., Chapman, C., Correa, L.D., Stebbins, K.J., Bundey, R.A., Prodanovich, P.C., Fagan, P., Baccei, C.S., Santini, A.M., Hutchinson, J.H., Seiders, T.J., Parr, T.A., Prasit, P., Evans, J.F., Lorrain, D.S., A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol. 160:7 (2010), 1699–1713, 10.1111/j.1476-5381.2010.00828.x.
48. Tager, A.M., LaCamera, P., Shea, B.S., Campanella, G.S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B.A., Kim, N.D., Hart, W.K., Pardo, A., Blackwell, T.S., Xu, Y., Chun, J., Luster, A.D., The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14:1 (2008), 45–54, 10.1038/nm1685.
49. Funke, M., Zhao, Z., Xu, Y., Chun, J., Tager, A.M., The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am. J. Respir. Cell Mol. Biol. 46:3 (2012), 355–364, 10.1165/rcmb.2010-0155OC.
50. Oikonomou, N., Mouratis, M.A., Tzouvelekis, A., Kaffe, E., Valavanis, C., Vilaras, G., Karameris, A., Prestwich, G.D., Bouros, D., Aidinis, V., Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 47:5 (2012), 566–574, 10.1165/rcmb.2012-0004OC.
51. van der Aar, E.M., Heckmann, B., Blanque, R., Desroy, N., Dupont, S., Cottereaux, C., Monjardet, A., Wakselman, E., Dirven, D., Christophe, T., Hrvacic, B., Ralic, J., Marsais, F., Brys, R., Pharmacological profile and efficacy of GLPG1690, a novel autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 193, 2016 A4532.
52. Ongenaert, M., Dupont, S., Blanqué, R., Brys, R., van der Aar, E., Heckmann, B., Strong reversal of the lung fibrosis disease signature by autotoxin GLP1690 in a mouse model for IPF. Eur. Respir. J., 48(60), 2016 OA4540.
53. van der Aar, E.M., Fagard, L., Desrivot, J., Dupont, S., Heckmann, B., Blanque, R., Gheyle, L., Ralic, J., Vanhoutte, F., Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 193, 2016 A1968.
54. Gagnon, L., Tremblay, M., Sarra-Bournet, F., Gervais, L., Felton, A., Leduc, M., Abbott, S., Duceppe, J.-S., Zacharie, B., Penney, C., Laurin, P., Grouix, B., PBI-4050 reduces inflammatory/fibrotic markers in a bleomycin-induced lung fibrosis model: a comparative study with pirfenidone. Am. J. Respir. Crit. Care Med., 189, 2014 A1968.
55. Gagnon, L., Leduc, M., Grouix, B., Tremblay, M., Sarra-Bournet, F., Geerts, L., Hince, K., Gervais, L., Felton, A., Cloutier, M.-P., Abbott, S., Duceppe, J.-S., Zacharie, B., Laurin. Oral treatment with PBI-4050 reduces lung fibrosis. Am. J. Respir. Crit. Care Med., 2015, 191 A3467.
56. Gagnon, L., Tremblay, M., Sarra-Bournet, F., Felton, A., Gervais, L., Leduc, M., Abbott, S., Duceppe, J.-S., Zacharie, B., Laurin, P., Grouix, B., PBI-4050 reduces inflammatory/fibrotic markers in a bleomycin-induced lung fibrosis model: a comparative study with nintedanib. Am. J. Respir. Crit. Care Med., 191, 2015 A3468.
57. Gagnon, L., Leduc, M., Grouix, B., Tremblay, M., Sarra-Bournet, F., Laverdure, A., Gagnon, W., Geerts, L., Hince, K., Gervais, L., Cloutier, M., Abbott, S., Duceppe, J., Zacharie, B., Laurin, P., Oral treatment with PBI-4050 reduces plasminogen activator inhibitor-1 (PAI-1), alpha-smooth muscle actin (α-SMA) and collagen expression in human fibroblasts and mice fibrotic lungs. Am. J. Respir. Crit. Care Med., 193, 2016 A5936.
58. Grouix, B., Tremblay, M., Sarra-Bournet, F., Felton, A., Leduc, M., Abbott, S., Duceppe, J.-S., Zacharie, B., Penney, C., Laiurin, P., Gagnon, L., A novel, first in class anti-fibrotic compound, PBI-4050, reduces ling fibrosis in the bleomycin-induced lung fibrosis model. September 2014, International Colloquium on Lung and Airway Fibrosis (ICLAF), Mont Tremblant, Quebec, Canada, 20–24 Available at: http://iclaf.com/conference/index.php/2014/ICLAF/paper/view/91 Accessed 2 December 2016.
59. Leduc, N., Trembley, M., Grouix, B., Sarra- Bournet, F., Felton, A., Laurin, P., Gagnon, L., Pbi-4050, a novel first-in class anti-fibrotic compound inhibits CTgf and collagen I production in human alveolar epithelial cells and fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model. Am. J. Respir. Crit. Care Med., 189, 2014 A1998.
60. ProMetic, ProMetic's PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial. Available at: http://www.prometic.com/prometics-pbi-4050-efficacy-further-evidenced-in-type-2-diabetic-and-metabolic-syndrome-clinical-trial/ Accessed 2 December 2016.
61. Parker, J., Sawtell, R., Gagnon, L., Hagerimania, A., Laurin, P., Kolb, M., Moran, J., PBI-4050 is safe and well tolerated and shows evidence of benefit in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 195, 2017 A7606.
62. Mastuda, K., MN-001 (Tipelukast), a nonselective phosphodiesterase, 5-lipoxygenase, leukotriene, phospholipase C and thromboxane A2 inhibitor, demonstrates anti-fibrotic effects in the bleomycin-induced idiopathic pulmonary fibrosis mouse. September 2014, International Colloquium on Lung and Airway Fibrosis (ICLAF), Mont Tremblant, Quebec, Canada, 20–24 Available at: http://www.iclaf.com/conference/index.php/2014/ICLAF/paper/view/37 Accessed December 2016.
63. Wilborn, J., Bailie, M., Coffey, M., Burdick, M., Strieter, R., Peters-Golden, M., Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. 97:8 (1996), 1827–1836, 10.1172/JCI118612.
64. MediciNova, MN-001: fibrotic diseases. About MN-001. Available at: http://medicinova.com/clinical-development/core/mn-001-nash/ Accessed 2 December 2016.
65. Horan, G.S., Wood, S., Ona, V., Li, D.J., Lukashev, M.E., Weinreb, P.H., Simon, K.J., Hahm, K., Allaire, N.E., Rinaldi, N.J., Goyal, J., Feghali-Bostwick, C.A., Matteson, E.L., O'Hara, C., Lafyatis, R., Davis, G.S., Huang, X., Sheppard, D., Violette, S.M., Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 177:1 (2008), 56–65, 10.1164/rccm.200706-805OC.
66. Getsy, J.A., Harper, D., Levy, M., Burggraaf, J., Moerland, M., de Visser, I., Wijsenbeek, M., Van den Blink, B., Gumbhir-Shah, K., Cohen, A., Lupher, M., The effect of recombinant human pentraxin-2 (PRM-151), on circulating fibrocytes in idiopathic pulmonary fibrosis (IPF). Am. J. Respir. Crit. Care Med., 183, 2011 A3803.
67. Shao, D.D., Suresh, R., Vakil, V., Gomer, R.H., Pilling, D., Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J. Leukoc. Biol. 83:6 (2008), 1323–1333, 10.1189/jlb.1107782.
68. Murray, L.A., Rosada, R., Moreira, A.P., Joshi, A., Kramer, M.S., Hesson, D.P., Argentieri, R.L., Mathai, S., Gulati, M., Herzog, E.L., Hogaboam, C.M., Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One, 5(3), 2010, e9683, 10.1371/journal.pone.0009683.
69. Pilling, D., Roife, D., Wang, M., Ronkainen, S.D., Crawford, J.R., Travis, E.L., Gomer, R.H., Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J. Immunol. 179:6 (2007), 4035–4044, 10.4049/jimmunol.179.6.4035.
70. Murray, L.A., Chen, Q., Kramer, M.S., Hesson, D.P., Argentieri, R.L., Peng, X., Gulati, M., Homer, R.J., Russell, T., van Rooijen, N., Elias, J.A., Hogaboam, C.M., Herzog EL.TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int. J. Biochem. Cell Biol. 43:1 (2011), 154–162, 10.1016/j.biocel.2010.10.013.
71. van den Blink, B., Dillingh, M.R., Ginns, L.C., Morrison, L.D., Moerland, M., Wijsenbeek, M., Trehu, E.G., Bartholmai, B.J., Burggraaf, J., Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur. Respir. J. 47:3 (2016), 889–897, 10.1183/13993003.00850-2015.
72. van den Blink, B., Burggraaf, J., Morrison, L.D., Ginns, L.C., Wijsenbeek, M.S., Moerland, M., et al. A Phase I study of PRM-151 in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 187, 2013 A5705.
73. Knipe, R.S., Tager, A.M., Liao, J.K., The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol. Rev. 67:1 (2015), 103–117, 10.1124/pr.114.009381.
74. Zhou, Y., Huang, X., Hecker, L., Kurundkar, D., Kurundkar, A., Liu, H., Jin, T.H., Desai, L., Bernard, K., Thannickal, V.J., Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J. Clin. Invest. 123:3 (2013), 1096–1108, 10.1172/JCI66700.
75. Waksal, S.D., Kadmon. Jeffries healthcare conference 2015. Available at: http://www.jefferies.com/CMSFiles/Jefferies.com/files/Kadmon(1).pdf Accessed 2 December 2016.
76. Ultsch, M., Bevers, J., Nakamura, G., Vandlen, R., Kelley, R.F., Wu, L.C., Eigenbrot, C., Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J. Mol. Biol. 425:8 (2013), 1330–1339, 10.1016/j.jmb.2013.01.024.
77. Murray, L.A., Zhang, H., Oak, S.R., Coelho, A.L., Herath, A., Flaherty, K.R., Lee, J., Bell, M., Knight, D.A., Martinez, F.J., Sleeman, M.A., Herzog, E.L., Hogaboam, C.M., Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am. J. Respir. Cell Mol. Biol. 50:5 (2014), 985–994, 10.1165/rcmb.2013-0342OC.
78. Hanania, N.A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S.K., Cheu, M., Putnam, W.S., Murray, E., Scheerens, H., Holweg, C.T., Maciuca, R., Gray, S., Doyle, R., McClintock, D., Olsson, J., Matthews, J.G., Yen, K., Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70:8 (2015), 748–756, 10.1136/thoraxjnl-2014-206719.
79. Yu, H., Lange, C., Wille, A., Siebers, U., Rao, E., Resnick, R., Duguid, M., Pritsker, A., Esperet, C., Soubrane, C., Yabkowitz, R., Subramaniam, A., SAR156597, an IL4/IL13 Bi-specific MAb, possesses a unique MoA in inhibition of IL13 signaling. September 2014, International Colloquium on Lung and Airway Fibrosis (ICLAF), Mont Tremblant, Quebec, Canada, 20–24 Available at: http://iclaf.com/conference/index.php/2014/ICLAF/paper/view/69 Accessed 2 December 2016.
80. Jakubzick, C., Choi, E.S., Joshi, B.H., Keane, M.P., Kunkel, S.L., Puri, R.K., Hogaboam, C.M., Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J. Immunol. 171:5 (2003), 2684–2693, 10.4049/jimmunol.171.5.2684.
81. Park, S.W., Ahn, M.H., Jang, H.K., Jang, A.S., Kim, D.J., Koh, E.S., Park, J.S., Uh, S.T., Kim, Y.H., Park, J.S., Paik, S.H., Shin, H.K., Youm, W., Park, C.S., Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J. Korean Med. Sci. 24:4 (2009), 614–620, 10.3346/jkms.2009.24.4.614.
82. Rao, E., Li, D., Underwood, S., Mikol, V., Davison, M., Kruip, J., Generation of a tetravalent bispecific antibody against IL4 and IL13 for the treatment of idiopathic pulmonary fibrosis. mAbs 4:1 (2012), 14–16.
83. Yang, J., Velikoff, M., Canalis, E., Horowitz, J.C., Kim, K.K., Activated alveolar epithelial cells initiate fibrosis through autocrine and paracrine secretion of connective tissue growth factor. Am. J. Physiol. Lung Cell Mol. Physiol. 306:8 (2014), L786–L796, 10.1152/ajplung.00243.2013.
84. Lipson, K.E., Wong, C., Teng, Y., Spong, S., CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenes. Tissue Repair, 5(Suppl 1), 2012, S24, 10.1186/1755-1536-5-S1-S24.
85. Wang, Q., Usinger, W., Nichols, B., Gray, J., Xu, L., Seeley, T.W., Brenner, M., Guo, G., Zhang, W., Oliver, N., Lin, A., Yeowell, D., Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenes. Tissue Repair, 4(1), 2011, 4, 10.1186/1755-1536-4-4.
86. Kono, M., Nakamura, Y., Suda, T., Kato, M., Kaida, Y., Hashimoto, D., Inui, N., Hamada, E., Miyazaki, O., Kurashita, S., Fukamachi, I., Endo, K., Ng, P.S., Takehara, K., Nakamura, H., Maekawa, M., Chida, K., Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin. Chim. Acta 412:23–24 (2011), 2211–2215, 10.1016/j.cca.2011.08.008.
87. Pan, L.H., Yamauchi, K., Uzuki, M., Nakanishi, T., Takigawa, M., Inoue, H., Sawai, T., Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur. Respir. J. 17:6 (2001), 1220–1227.
88. Raghu, G., Scholand, M.B., de Andrade, J., Lancaster, L., Mageto, Y., Goldin, J., Brown, K.K., Flaherty, K.R., Wencel, M., Wanger, J., Neff, T., Valone, F., Stauffer, J., Porter, S., FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur. Respir. J. 47:5 (2016), 1481–1491, 10.1183/13993003.01030-2015.
89. Oksenberg, D., Dufu, K., Patel, M.P., Chuang, C., Li, Z., Xu, Q., Silva-Garcia, A., Zhou, C., Hutchaleelaha, A., Patskovska, L., Patskovsky, Y., Almo, S.C., Sinha, U., Metcalf, B.W., Archer, D.R., GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br. J. Haematol. 175:1 (2016), 141–153, 10.1111/bjh.14214.
90. Bennett, B., Blease, K., Ye, Y., Azaryan, A., Ramirez-Valle, F., Ceres, R., Horan, G., Schafer, P., Van Der Velden JL, Janssen-Heininger YMW. CC-90001, a second generation Jun N-terminal kinase (JNK) inhibitor for the treatment of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 195, 2017 A5409.
91. Wuyts, W.A., Antoniou, K.M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J.C., Maher, T.M., Poletti, V., Richeldi, L., Vancheri, C., Wells, A.U., Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respir. Med. 2:11 (2014), 933–942, 10.1016/S2213-2600(14)70232-2.
92. Wells, A., Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard. Eur. Respir. J. 45:5 (2015), 1208–1210, 10.1183/09031936.00043915.
93. Saito, M., Yamazaki, M., Maeda, T., Matsumura, H., Setoguchi, Y., Tsuboi, R., Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction. Arch. Dermatol Res. 304 (2012), 217–222, 10.1007/s00403-011-1184-2.
94. Shi, Q., Liu, X., Bai, Y., Cui, C., Li, J., Li, Y., Hu, S., Wei, Y., In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One, 6, 2011, 10.1371/journal.pone.0028134 e28134.
95. Iyer, S.N., Gurujeyalakshmi, G., Giri, S.N., Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291:1 (1999), 367–373.